Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status"

被引：3
作者：
Pappagallo, Marco [1 ]
Inturrisi, Charles E. [1 ]
Manfredi, Paolo L. [1 ]
机构：
[1] Relmada Therapeut Inc, 2222 Ponce Leon Blvd Floor 3, Coral Gables, FL 33134 USA
来源：
CNS DRUGS | 2022年 / 36卷 / 02期
关键词：
METHADONE;
D O I：
10.1007/s40263-021-00891-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：203 / 204
页数：2
相关论文
共 8 条
  • [1] EDDY N B, 1957, Bull World Health Organ, V17, P569
  • [2] Gorman AL, 1997, NEUROSCI LETT, V223, P5
  • [3] Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
    Henter, Ioline D.
    Park, Lawrence T.
    Zarate, Carlos A., Jr.
    [J]. CNS DRUGS, 2021, 35 (05) : 527 - 543
  • [4] ISBELL H, 1948, J PHARMACOL EXP THER, V93, P305
  • [5] Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat
    Lemberg, Kim
    Kontinen, Vesa K.
    Viljakka, Kaarin
    Kylanlahti, Irene
    Yli-Kauhaluoma, Jari
    Kalso, Eija
    [J]. ANESTHESIA AND ANALGESIA, 2006, 102 (06) : 1768 - 1774
  • [6] Mu Opioids and Their Receptors: Evolution of a Concept
    Pasternak, Gavril W.
    Pan, Ying-Xian
    [J]. PHARMACOLOGICAL REVIEWS, 2013, 65 (04) : 1257 - 1317
  • [7] Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: Clinical results from an open study
    Soyka, Michael
    Zingg, Christina
    [J]. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2009, 10 (03) : 217 - 224
  • [8] US Drug Enforcement Administration, 2020, DRUG CHEM INF SECT M
1